Neuroprotective Effects of Intravenous Anesthetics: A New Critical Perspective

ISSN: 1873-4286 (Online)
ISSN: 1381-6128 (Print)


Volume 20, 42 Issues, 2014


Download PDF Flyer




Current Pharmaceutical Design

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 62nd of 254 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.288
5 - Year: 3.555

Neuroprotective Effects of Intravenous Anesthetics: A New Critical Perspective

Author(s): Federico Bilotta, Elisabetta Stazi, Alexander Zlotnik, Shaun E. Guenbaum and Giovanni Rosa

Affiliation: Department of Anesthesiology, Critical Care and Pain Medicine, “Sapienza” University Rome, Italy

Abstract

Perioperative cerebral damage can result in various clinical sequela ranging from minor neurocognitive deficits to catastrophic neurological morbidity with permanent impairment and death. The goal of neuroprotective treatments is to reduce the clinical effects of cerebral damage through two major mechanisms: increased tolerance of neurological tissue to ischemia and changes in intra-cellular responses to energy supply deprivation. In this review, we present the clinical evidence of intravenous anesthetics on perioperative neuroprotection, and we also provide a critical perspective for future studies. The neuroprotective efficacy of the intravenous anesthetics thiopental, propofol and etomidate is unproven. Lidocaine may be neuroprotective in non-diabetic patients undergoing cardiac surgery with cardiopulmonary bypass (CBP) or with a 48-hour infusion, but conclusive data are lacking. There are several limitations of clinical studies that evaluate postoperative cognitive dysfunction (POCD), including difficulties in identifying patients at high-risk and a lack of consensus for defining the “gold-standard” neuropsychological testing. Although a battery of neurocognitive tests remains the primary method for diagnosing POCD, recent evidence suggests a role for novel biomarkers and neuroimaging to preemptively identify patients more susceptible to cognitive decline in the perioperative period. Current evidence, while inconclusive, suggest that intravenous anesthetics may be both neuroprotective and neurotoxic in the perioperative period. A critical analysis on data recorded from randomized control trials (RCTs) is essential in identifying patients who may benefit or be harmed by a particular anesthetic. RCTs will also contribute to defining methodologies for future studies on the neuroprotective effects of intravenous anesthetics

Keywords: Neuroprotection, intravenous anesthetic, neurotoxicity, neuropsychological testing

Purchase Online Rights and Permissions

  
  



Article Details

Volume: 20
First Page: 1
Last Page: 7
Page Count: 7
DOI: 10.2174/1381612820666140325110113
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science